These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2208346)

  • 21. The epidemiology of influenza in children hospitalized in Canada, 2004-2005, in Immunization Monitoring Program Active (IMPACT) centres.
    Can Commun Dis Rep; 2006 Apr; 32(7):77-86. PubMed ID: 16649286
    [No Abstract]   [Full Text] [Related]  

  • 22. Extensive limb swelling after immunization: reports to the Vaccine Adverse Event Reporting System.
    Woo EJ; Burwen DR; Gatumu SN; Ball R;
    Clin Infect Dis; 2003 Aug; 37(3):351-8. PubMed ID: 12884159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety monitoring in vaccine development and immunization.
    Lee CJ; Lee LH; Lu CH; Huang YJ; Chu ML
    Acta Paediatr Taiwan; 2006; 47(1):7-13. PubMed ID: 17016963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reporting of adverse events following immunization in Australia.
    Isaacs D; Lawrence G; Boyd I; Ronaldson K; McEwen J
    J Paediatr Child Health; 2005 Apr; 41(4):163-6. PubMed ID: 15813867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Routine vaccines across the life span, 2007.
    Zimmerman RK; Middleton DB; Burns IT; Clover RD; Kimmel SR
    J Fam Pract; 2007 Feb; 56(2 Suppl Vaccines):S18-37, C1-3. PubMed ID: 17270108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine supply and quality. Surveillance of adverse events following immunization.
    Wkly Epidemiol Rec; 1996 Aug; 71(32):237-42. PubMed ID: 8924387
    [No Abstract]   [Full Text] [Related]  

  • 27. Improving global monitoring of vaccine safety: a quantitative analysis of adverse event reports in the WHO Adverse Reactions Database.
    Letourneau M; Wells G; Walop W; Duclos P
    Vaccine; 2008 Feb; 26(9):1185-94. PubMed ID: 18243428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system.
    Budnitz DS; Pollock DA; Mendelsohn AB; Weidenbach KN; McDonald AK; Annest JL
    Ann Emerg Med; 2005 Feb; 45(2):197-206. PubMed ID: 15671977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meningococcal disease in Canada. Surveillance summary to 1987.
    Varughese PV; Carter AO
    Can Dis Wkly Rep; 1989 Apr; 15(17):89-96. PubMed ID: 2720807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The WHO Global Programme for Vaccines and Immunization Vaccine Trial Registry.
    Robertson SE; Mayans MV; Horsfall S; Wright PF; Clemens J; Ivanoff B; Lambert PH
    Bull World Health Organ; 1997; 75(4):295-305. PubMed ID: 9342888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Prevention of contagious diseases].
    Wehrlin N
    Rev Infirm; 1981 Apr; 31(7):35-42. PubMed ID: 6910084
    [No Abstract]   [Full Text] [Related]  

  • 32. [Rational use of vaccinations].
    Rey M
    Rev Prat; 1984 Jun; 34(31):1641-55. PubMed ID: 6740169
    [No Abstract]   [Full Text] [Related]  

  • 33. Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999-2005.
    Fernandes GC; Camacho LA; Sá Carvalho M; Batista M; de Almeida SM
    Vaccine; 2007 Apr; 25(16):3124-8. PubMed ID: 17316927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Supplementary report: Surveillance of adverse events following immunisation among children aged less than seven years in Australia, 1 January to 30 June 2011.
    Mahajan D; Cook J; McIntyre P; Macartney K; Menzies R
    Commun Dis Intell Q Rep; 2012 Mar; 36(1):114-9. PubMed ID: 23153088
    [No Abstract]   [Full Text] [Related]  

  • 35. Suggestions for improving the monitoring of adverse events following immunization in New Zealand.
    Miller M; Turner N
    N Z Med J; 2002 Sep; 115(1162):U186. PubMed ID: 12386665
    [No Abstract]   [Full Text] [Related]  

  • 36. Surveillance of congenital rubella syndrome and other rubella-associated adverse pregnancy outcomes.
    Can Commun Dis Rep; 1996 Mar; 22(5):35-7. PubMed ID: 8680371
    [No Abstract]   [Full Text] [Related]  

  • 37. Standards for child and adolescent immunization practices. National Vaccine Advisory Committee.
    National Vaccine Advisory Committee
    Pediatrics; 2003 Oct; 112(4):958-63. PubMed ID: 14523192
    [No Abstract]   [Full Text] [Related]  

  • 38. Enhanced surveillance of invasive meningococcal disease in Canada: 1 January, 2002, through 31 December, 2003.
    Can Commun Dis Rep; 2006 Apr; 32(8):97-107. PubMed ID: 16685767
    [No Abstract]   [Full Text] [Related]  

  • 39. Communicable Diseases Surveillance.
    Commun Dis Intell; 1999 May; 23(5):132-9. PubMed ID: 10429315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada.
    Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R;
    Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.